FDA Purple Book · Reference family
palivizumab (Synagis)
palivizumab is an FDA-licensed reference biologic from Swedish Orphan Biovitrum AB (publ). Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2004
Reference approved
Reference product
351(a)BLA 103770
Synagis palivizumab
Swedish Orphan Biovitrum AB (publ)
- Approved
- Jul 23, 2004
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for palivizumab, in chronological order.
Reference approval
Approval date of the reference palivizumab product.
22 yr 2 mo ago
Frequently asked questions
Are there biosimilars approved for palivizumab (Synagis)?
No 351(k) biosimilars or interchangeable biosimilars referencing palivizumab are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.